艾迪注射液联合TPF方案治疗晚期胃癌疗效观察

Clinical Efficacy of Aidi Injection Combined with TPF in the Treatment of Advanced Gastric Carcinoma

目的比较艾迪注射液-TPF方案与TPF方案治疗Ⅲb～IV期胃癌的疗效及不良反应。方法将Ⅲb-Ⅳ期胃癌患者60例随机分为两组,均予常规化疗方案,治疗组加用艾迪注射液;28d为1个周期,连用2个周期。结果治疗组有效率53.3%,对照组50%,两组比较差异无统计学意义(P>0.05),治疗组Karnofsky评分提高率高于对照组(P<0.05)。白细胞下降发生率治疗组和对照组分别为63.3%和83.3%,恶心呕吐发生率两组分别为66.7%和86.7%(P<0.05)。结论艾迪注射液联合TPF方案治疗进展期胃癌,可降低化疗对患者免疫功能的影响及不良反应发生率,改善患者的生活质量。艾迪注射液配合TPF方案与单纯TPF方案治疗晚期胃癌的客观疗效相近,但前者不良反应小,中位生存期长。

Objective To compare therapy efficacy and adverse reactions of the Aidi injection-TPF and the TPF program alone in the treatment of Ⅲ[ b - Ⅳ gastric cancer. Methods Sixty cases of 11I b ~ IV gastric cancer patients were randomly divided into two groups. Both groups received conventional chemotherapy,and Aidi injection was added to the treatment group for two cycles with 28 days as a cycle. Results The effective rate of the treatment group was 53.3% and that of the control group 50% ,with no significant difference between the two groups（P〉 0.05 ）,and the increase rate of Karnofsky score was higher in the treatment group than that in the control group（P〈 0.05 ）. The incidence of the interleukin decline of the treatment group and control group was 63.3% and 83.3% ,respectively,and the incidence of nausea and vomiting was 66.7% and 86.7% ,respectively（P〈 0.05）. Conclusion Aidi injection combined with TPF in the treatment of advanced gastric cancer can reduce the impact of chemotherapy on the patient immune function and the incidence of adverse reactions and improve the quality of life. Both Aidi injection with TPF and the TPF program alone in the treatment of advanced gastric cancer have similar therapy efficacy objectively, but the former has fewer adverse reactions and longer median survival time.